--U.S. government researchers are planning studies of how often and why coronavirus levels rebound in some patients who have completed a five-day treatment course of Pfizer Inc.'s Paxlovid, Bloomberg reported.
--The National Institute of Allergy and Infectious Diseases is discussing a variety of possible epidemiological and clinical studies to examine post-Paxlovid rebound with scientists at the Centers for Disease Control and Prevention, the report said.
--The NIH hopes to get a better sense of how often viral rebounds occur after the Paxlovid treatment course, who is at risk for relapse and whether it could be avoided with a longer regimen, among other questions, Bloomberg reported.
--Pfizer's own final-stage study showed that "a small number" of patients experienced a rebound after being treated with either the drug or a placebo, the report said, citing a statement from the company. Pfizer said the rate of rebound was no higher among those who received Paxlovid than placebo recipients, adding it had seen no evidence of resistance to the medication.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.